Poseida Therapeutics (NASDAQ:PSTX) Given Neutral Rating at BTIG Research

Poseida Therapeutics (NASDAQ:PSTX)‘s stock had its “neutral” rating restated by equities research analysts at BTIG Research in a research note issued to investors on Tuesday,Benzinga reports.

PSTX has been the topic of a number of other research reports. William Blair reiterated a “market perform” rating on shares of Poseida Therapeutics in a report on Tuesday. HC Wainwright restated a “neutral” rating and set a $9.00 price target (down from $20.00) on shares of Poseida Therapeutics in a report on Tuesday.

Poseida Therapeutics Trading Up 228.0 %

Shares of NASDAQ:PSTX traded up $6.52 during mid-day trading on Tuesday, hitting $9.38. The stock had a trading volume of 23,895,769 shares, compared to its average volume of 658,982. The company’s 50 day moving average is $2.78 and its 200-day moving average is $2.92. Poseida Therapeutics has a 12-month low of $1.87 and a 12-month high of $9.41. The company has a debt-to-equity ratio of 0.68, a quick ratio of 3.20 and a current ratio of 3.20. The company has a market cap of $914.17 million, a PE ratio of -14.89 and a beta of 0.54.

Institutional Investors Weigh In On Poseida Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. Bayesian Capital Management LP bought a new stake in Poseida Therapeutics in the first quarter worth $33,000. Marshall Wace LLP bought a new stake in shares of Poseida Therapeutics during the 2nd quarter worth about $31,000. Rothschild Investment LLC acquired a new position in shares of Poseida Therapeutics during the 2nd quarter valued at about $35,000. Principal Financial Group Inc. acquired a new position in shares of Poseida Therapeutics during the 2nd quarter valued at about $35,000. Finally, Virtu Financial LLC bought a new position in shares of Poseida Therapeutics in the 3rd quarter valued at approximately $37,000. 46.87% of the stock is owned by hedge funds and other institutional investors.

Poseida Therapeutics Company Profile

Poseida Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications.